Friday, May 25, 2012

Genentech ups battle on cancer

(San Francisco Business Times subscription required.)

Three years after outsiders worried that Roche’s $47 billion buyout would downgrade the company’s revered research group, the Food and Drug Administration next month could give the legendary South San Francisco biotech company its third drug approval in the past 10 months.
What’s more, Genentech expects to file later this year for FDA approval of another highly targeted and less toxic cancer-fighting drug.
But it isn’t only drugs that were already in the clinic at the time of the Roche deal that have Genentech scientists excited.

No comments:

Post a Comment